AMLX
Income statement / Annual
Last year (2024), Amylyx Pharmaceuticals, Inc.'s total revenue was $87.37 M,
a decrease of 77.06% from the previous year.
In 2024, Amylyx Pharmaceuticals, Inc.'s net income was -$301.74 M.
See Amylyx Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$87.37 M |
$380.79 M |
$22.23 M |
$0.00 |
$650.00 K |
$1.43 M |
| Cost of Revenue |
$42.16 M
|
$25.44 M
|
$2.99 M
|
$0.00
|
$24.59 M
|
$11.90 M
|
| Gross Profit |
$45.22 M
|
$355.35 M
|
$19.24 M
|
$0.00
|
-$23.94 M
|
-$10.47 M
|
| Gross Profit Ratio |
0.52
|
0.93
|
0.87
|
0
|
-36.84
|
-7.34
|
| Research and Development Expenses |
$104.08 M
|
$128.19 M
|
$93.45 M
|
$44.04 M
|
$24.59 M
|
$11.90 M
|
| General & Administrative Expenses |
$111.63 M
|
$178.86 M
|
$122.73 M
|
$38.93 M
|
$14.86 M
|
$3.08 M
|
| Selling & Marketing Expenses |
$2.70 M
|
$9.50 M
|
$4.40 M
|
$0.00
|
$200.00 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$114.33 M
|
$188.36 M
|
$127.13 M
|
$38.93 M
|
$15.06 M
|
$3.08 M
|
| Other Expenses |
$141.53 M
|
$0.00
|
$0.00
|
-$285.00 K
|
-$24.59 M
|
-$1.43 M
|
| Operating Expenses |
$359.95 M
|
$316.54 M
|
$220.58 M
|
$82.69 M
|
$15.06 M
|
$13.55 M
|
| Cost And Expenses |
$402.10 M
|
$341.98 M
|
$223.57 M
|
$82.69 M
|
$39.66 M
|
$13.55 M
|
| Interest Income |
$13.81 M
|
$16.16 M
|
$4.29 M
|
$36.00 K
|
$14.00 K
|
$176.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.29 M
|
$1.28 M
|
| Depreciation & Amortization |
$904.00 K
|
$1.09 M
|
$487.00 K
|
$52.00 K
|
$1.00 K
|
$13.55 M
|
| EBITDA |
-$290.98 M |
$39.89 M |
-$200.85 M |
-$82.64 M |
-$39.00 M |
$1.11 M |
| EBITDA Ratio |
-3.33
|
0.1
|
-9.04
|
0
|
-60.01
|
0.78
|
| Operating Income Ratio |
-3.6
|
0.1
|
-9.06
|
0
|
-60.01
|
-9.5
|
| Total Other Income/Expenses Net |
$12.60 M
|
$15.50 M
|
$3.74 M
|
-$5.24 M
|
-$3.28 M
|
-$162.00 K
|
| Income Before Tax |
-$302.14 M
|
$54.30 M
|
-$197.60 M
|
-$87.93 M
|
-$42.28 M
|
-$13.72 M
|
| Income Before Tax Ratio |
-3.46
|
0.14
|
-8.89
|
0
|
-65.05
|
-9.62
|
| Income Tax Expense |
-$393.00 K
|
$5.03 M
|
$774.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$301.74 M
|
$49.27 M
|
-$198.38 M
|
-$87.93 M
|
-$42.28 M
|
-$14.82 M
|
| Net Income Ratio |
-3.45
|
0.13
|
-8.92
|
0
|
-65.05
|
-10.39
|
| EPS |
-4.43 |
0.73 |
-2.98 |
-1.52 |
-0.79 |
-0.26 |
| EPS Diluted |
-4.43 |
0.7 |
-2.98 |
-1.52 |
-0.79 |
-0.26 |
| Weighted Average Shares Out |
$68.14 M
|
$67.23 M
|
$66.51 M
|
$57.86 M
|
$56.47 M
|
$56.47 M
|
| Weighted Average Shares Out Diluted |
$68.14 M
|
$69.99 M
|
$66.51 M
|
$57.86 M
|
$56.47 M
|
$56.47 M
|
| Link |
|
|
|
|
|
|
